Background: Antibody-dependent cellular cytotoxicity (ADCC) activity has been described as a potential immune correlate of protection from HIV infection in macaques and humans. The role of ADCC activity mediated by passively acquired antibodies (Abs) in HIV-exposed infants is unknown and was examined to determine if pre-existing HIV-specific antibodies provide protection from infection and/or disease progression.
Methods: We evaluated the ADCC activity of passively acquired Abs in the first week of life from infants of HIV-positive mothers. Infants were included based on the following criteria: HIV-RNA negative at birth, breastfed ≥3 months, ≥6 months follow-up of negative infants. Seventy-two infants were included, 21 of who were first detected as HIV positive after birth. Infant plasmas were tested against an infant-derived, subtype A envelope using a rapid fluorometric ADCC assay. HIV-specific IgG1 was measured by binding to gp120 coated target cells and quantified by flow cytometry. IgG3 HIV-specific Ab titers were measured by ELISA. Comparisons of measurements in infected and uninfected infants were made by 2-sided Welch’s t-test. Survival analyses were conducted using Cox-proportional hazards models. Spearman’s rank correlation was used for correlation analyses.
Results: Passively acquired ADCC activity was higher in uninfected infants than infected infants, but was not statistically significant (p=0.12). In infected infants, pre-existing ADCC activity was associated with increased survival: each 10% increase in ADCC activity was associated with a 49.1% reduction in the risk of mortality (p=0.03). ADCC activity positively correlated with the magnitude of HIV-specific IgG1 surface binding, measured as log2MFI(r=0.92, p<0.0001). The magnitude of surface IgG1 binding was also associated with survival in infected infants (HR:0.24, p=0.005). IgG3 binding Ab end point titers were not associated with infant infection (p=0.25) or survival (p=0.63). In measurements of longitudinal ADCC activity from 6 infected infants, passively acquired ADCC activity declined to undetectable levels prior to an increase in de novo responses. De novo ADCC responses did not correlate with passively acquired responses (r=-0.14, p=0.79).
Conclusions: These data suggest that HIV-specific, ADCC-mediating passively acquired Abs may impact disease progression and survival among infected infants. In particular, IgG1 and not IgG3 Abs appear to be responsible for the effect and de novo responses do not explain the survival benefit.